Most men dream of maintaining an erection, but as Mr Henry Wolf found, it continually lasting for nearly two years is a nightmare.

Mr Wolf from California embarked on a four hour round trip on his 1993 BMW motorcycle in May, 2010. The motorcycle was not the fitted with the original seat, the seat in question was manufactured by Corbin-Pacific, but BMW are also being sued.

He claims that after the journey he developed Priapism, a condition that is diagnosed if an erection continues beyond four hours, for no normal reasons. There are two types of priapism, high and low flow, only 10-20% is attributed to high flow. Low flow is blood not going back into body and high flow is due to a bypassing vascular problem. Some medical conditions can cause it, including ED treatments such as intra-cavernous injections.

Vernon Bradley, his attorney said “It’s very embarrassing, and all kind of problems developed. He had to reconfigure his clothing, and going to the bathroom was a problem.” This was in an interview that Mr Bradley had with ABC News. His condition has reversed recently and Mr Wolf can no longer able to get or maintain an erection. In his search for help with this ailment Mr Wolf has consulted many doctors in regard to his plight. They are in agreement that it was a combination of the long motorbike jaunt and the dynamics of the seat.

At the University of Miami’s urology department, Dr. Ramgopal Satyanarayana said he had never heard of priapism induced by a motorbike saddle. On rare occasions it could be caused by injury, but generally it is a result of using well known ED medications like Cialis or Viagra, also antipsychotics.

“For treatment, we tell them to take pseudoephedrine, and if that doesn’t bring it down, we actually inject medications that can arrest the amount of blood coming in. If that doesn’t work, we have to operatively reduce it,” said Dr Satyanarayana.

Treatment for priapism should be swift as ED is an unfortunate but common outcome. The consultants trying to treat Mr Wolf have been using a conservative approach as the other extreme option would be surgery.

“If that surgery is not successful, he will never be able to get an erection with a pump or anything else,” his legal representative Mr Bradley said. The lawsuits are to be served, with a 30 day period for the companies involved to dispute claims. At present the amount of damages has not been revealed, but he is claiming that his subsequent condition has left him without a sex life causing him mental and emotional problems. Surely the fact that the bike had been modified to a ridged seat, not manufactured by BMW, would not lay the blame with BMW. Again it will be another claim that a well-known company has to defend at the cost to its customers and its good name.

Source: http://www.uk-med.co.uk/Health/The-Four-Hour-Motorbike-Ride-That-Caused-A-Two-Year-Erection

Visit the FDA on Facebook, Flickr, YouTube and Twitter

Article source: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302140

Read more below:

Oxytocin sometimes referred to as the cuddle hormone, has found to help the improvement of men’s sexual performance

Oxytocin is a natural chemical produced in the brain and released into the bloodstream.

This chemical has a natural bonding effect for new mothers and their babies. New recently discovered research has put Oxytocin on the same level as Viagra. One researcher, who had previously worked on the development of Viagra, was so impressed with the results his description of oxytocin was a ‘potential blockbuster’.

Oxytocin is a naturally made hormone in the body, both men and woman make the hormone, it helps with feelings or trust, confidence and sexual attraction. During labour woman produce oxytocin, this helps new mums to produce milk and helps with the natural bonding process between mum and baby.

Oxytocin has been proven to make men more sensitive and more compatible to their partner’s feelings, but other side effects to the male physique were not fully understood.

Californian researches have released information discovered about the drug. Research conducted on a married man with 3 children with social relationship problems, proved positive. The man had received conventional medication but all had proved unsuitable or had unwanted side effects. The hormone oxytocin was taken by spraying up the man’s nasal passage, two times daily. The results were very constructive, with the patients love life improving significantly, as well as his sexual drive, which was considered poor, improving greatly.

There were other side effects which were welcome, such as his affection towards his wife increased he felt closer to her and was a lot more tactile. His love life felt much more comfortable and relaxed, more fulfilling and enjoyable.

Unfortunately, not all of the side effects were considered positive. An incident at work proved a little embarrassing, the man involved in the test who has not normally given to showing affection, gave a work colleague a hug this was considered totally out of character. And once the medication was no longer taken the positive results no longer continued.

There are differences between Viagra and oxytocin, oxytocin is more active within the feelings and understandings of relationships, helping the medication taker to become more in tune and more understanding. Viagra works differently, it is more involved with the physical effects of love making and unfortunately is not always effective.

Sales for Viagra Cialis and Levitra have reached approximately 2.5 billion a year, there is obviously a worldwide need for the drug. Perhaps a new drug is needed, oxytocin is showing significant potential, but caution must always be followed with any new medication.

The drug watchdogs may be cautious with a medication that might have any changing emotional side effects.

Articel Source:http://www.uk-med.co.uk/Health/Viagra-or-Oxytocin-known-as-the-Cuddle-hormone-Which-one-is-best-for-Male-Sexual-Performance

MONDAY, March 5 (HealthDay News) — For years, women with the severe form of premenstrual syndrome known as premenstrual dysphoric disorder (PMDD) were told that their symptoms should subside the day menstruation begins.

Now, new research suggests that these symptoms, which can include serious mood swings, start about four days before menstruation and can linger through the first three days of menses — as many women with the disorder can attest.

This expanded PMDD definition will help researchers update the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), due out in May 2013. The DSM classifies mental disorders by precise definitions and diagnostic criteria, and it influences treatment decisions and insurance reimbursement.

“It was thought that PMDD symptoms would drop off sharply at the onset of menses, and now we realize they don’t,” said study author Dr. S. Ann Hartlage, director of the Marital and Sex Therapy Program at Rush University Medical Center, in Chicago.

Hartlage and colleagues surveyed more than 1,000 women with and without PMDD about their symptoms for one or two menstrual cycles.

PMDD differs from premenstrual syndrome (PMS) in the number of symptoms it includes and their severity. Both conditions may be marked by bloating, short-term weight gain, breast tenderness and certain mood changes. However, extreme mood changes, anxiety, depression, anger and irritability may occur with PMDD to such an extent that they interfere with functioning at work or at home.

Experts said the new findings, published in the March issue of the Archives of General Psychiatry, will affect how women with PMDD will be labeled.

“This revision of how PMDD is defined will have an impact on research studies down the line,” said Dr. Christopher Estes, an assistant professor of obstetrics and gynecology at the University of Miami Miller School of Medicine. “It expands the amount of time around and during the menstrual cycle when the symptoms can be categorized as PMDD.”

Treatment depends on PMDD symptoms. “There is a role for antidepressants and hormonal treatments like oral contraceptives,” Estes said. According to Hartlage, these sometimes are prescribed at lower doses than would be used to treat depression or anxiety.

PMS, on the other hand, is typically treated with lifestyle changes, such as regular exercise, eating a healthy diet and caffeine avoidance as well as prescription or over-the-counter medication, including nonsteroidal anti-inflammatory drugs.

The American College of Obstetricians and Gynecologists says that women considered to have PMS suffer for at least three menstrual cycles with at least one symptom, such as depression, insomnia or food cravings, that emerges within five days before a woman’s period and ends within four days after the start of menstrual flow. These emotional and/or physical symptoms interfere with some aspect of daily life but to a lesser extent than PMDD.

The number of symptoms required for a PMDD diagnosis needs further exploration, the authors commented. The DSM-IV, the current edition, requires five symptoms, while the authors found that some women are impaired with three or four symptoms. These women would be excluded under the current definition.

Dr. Donnica Moore, an obstetrician-gynecologist and president of Sapphire Women’s Health Group in Far Hills, N.J., said the study raises awareness among psychiatrists about the full scope of PMDD.

“It has been very clear to women all along that PMDD symptoms persist after the first day of menstruation,” Moore said. “If you have any kind of menstrual symptoms that interfere with your activities of daily living, whether physical or emotional, discuss them with your doctor.”

Article source: http://www.nlm.nih.gov/medlineplus/news/fullstory_122590.html

A study has found that freezing penile tissue causes a block for the nerves, enabling them to triple the length of duration, before ejaculation occurs. They tried the procedure on 24 men who hadn’t been helped by other treatments and medications, such as Viagra and Cialis, which are widely used for erectile dysfunction. Before the treatment the average time was 38 seconds prior to ejaculation, extended with the nerve block to 110 seconds. This would be the same result that you would expect with normal drug treatment.

With up to 38% of men being affected by premature ejaculation, it makes it the most frequent erectile dysfunction problem worldwide. Many treatments are available at present in tablet form, ointments and counselling.

The new procedure is an invasive treatment, by inserting a hollow needle just under the navel and being assisted by a computerised imaging device. They find one of the two dorsal penile nerves and freeze it, this is reported to not be of any discomfort, just a cold feeling. It takes about 45 minutes to perform and the patient is released from the clinic the same day, with an estimated cost when approved, of £2000.

As yet the recipients of the treatment, have not suffered any side effects. Although some did, 3 months post treatment, seemed to be experiencing ejaculating time shortening again. Bringing into question if it would have to be regularly administered, some test subjects are being monitored for more than 6 months.

It was asked at the conference as to how often you could repeat the treatment before damage occurred. Dr Prologo didn’t think there would be a long term problems as only one of the nerves will be destroyed. This is why another procedure is also under research using heat, which would not damage the nerve.

The results and new technique were revealed by J David Prologo MD, a professor of interventional radiology at Case Western Reserve University, in Cleveland and presented to the annual meeting of the Radiological Society of North America. Exponents’ of this procedure say that it could become a common treatment of dealing with this problem. As this work is in the early stages, other experts are sceptical of the future effects of the therapy and if men would take up the treatment.

At this time researchers are in the planning stages as to continued studies using a greater number of men for both procedures and also use of a placebo test.

Dapoxetine is a drug specifically developed for the on-demand treatment of PE and is the first oral medication (tablet) to be approved for this condition. Dapoxetine has been extensively evaluated in five randomised, placebo-controlled Phase III clinical trials involving more than 6,000 men with PE and their partners. This is the largest and most comprehensive clinical trial programme to date for a drug therapy to treat PE ^1-3. Dapoxetine is a unique, short-acting, selective serotonin reuptake inhibitor (SSRI) designed to be taken only when needed, that is 1–3 hours before sexual intercourse is anticipated, rather than every day ²
Dapoxetine will be marketed by Janssen-Cilag, marking another significant advance in the company’s commitment to developing innovative, high quality treatments for unmet medical needs..

“Dapoxetine is an important new medication for doctors and patients,” commented Professor Dr Hartmut Porst, Private Institute for Urology and Andrology, Hamburg, Germany. “The lack of a previously approved oral medication for PE has contributed to a substantial deficiency in the diagnosis and treatment of this common condition. For the first time, physicians will be able to provide men with a pharmaceutical product that has been specifically developed for PE and that is proven to be effective.”

Premature Ejaculation

PE is a distressing sexual dysfunction that can be present from the first sexual encounter or can develop later in life. Depending on the methodology and criteria used to evaluate the prevalence of PE in studies, the reported proportion of men affected with this condition at some point in their lives has ranged from 4–30% ⁴. Experts in PE from the International Society of Sexual Medicine (ISSM) define the condition as consisting of three major components: a short time to ejaculation, lack of ejaculatory control and negative personal impact or distress related to ejaculation. The condition is defined by the ISSM as “a male sexual dysfunction characterised by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy” ⁵. Unlike erectile dysfunction (ED), which tends to affect older men, PE has similar prevalence across all age groups ⁶. In fact, more men are believed to experience PE than ED ^{6, 7}.

A combination of physiological and psychological factors are believed to influence the mechanism of ejaculation ^{8, 9}. Men with PE appear to go through the same process of ejaculation as other men, but it happens more quickly and with a reduced feeling of control ⁶. Research suggests serotonin plays a central role in the timing of ejaculation ^8-10.

About dapoxetine

ALZA Corporation, a Janssen-Cilag affiliate, licensed dapoxetine from PPD-GenuPro in 2001 with exclusive worldwide rights to develop and commercialise the compound for urogenital therapies, including premature ejaculation.

The clinical trial programme for the use of dapoxetine in premature ejaculation was conducted by Johnson Johnson Pharmaceutical Research and Development. The product will be marketed by Janssen-Cilag in most countries where regulatory approval has been granted.

Product Availability

After approval in a specific country, Priligy (dapoxetine) will only be available by prescription from a healthcare professional.

The product is expected to be made available for purchase in licensed pharmacies in the countries where approved around April 2009, after all local regulatory requirements related to packaging and pricing are finalised. Janssen-Cilag will provide official confirmation of the exact date of product availability in each individual country. Applications for marketing authorisation in other countries are under review.

Unapproved imitations (counterfeit) of dapoxetine have been sold. Government officials from around the world have warned of the potential risks associated with counterfeit drugs, including the risk of death. As for any prescription medication, patients should buy Priligy (dapoxetine) only from a pharmacy that is officially licensed by government authorities. Patients should be especially cautious of internet pharmacies, as many of these are unlicensed.

About Janssen-Cilag

The Janssen-Cilag companies are part of the Johnson Johnson family of companies. They have a long track record in developing and marketing treatments for central nervous system disorders, pain management, oncology, infectious diseases, reproductive health and gastrointestinal disorders. More information about Janssen-Cilag can be found at www.janssen-cilag.com.

Johnson Johnson Pharmaceutical Research Development, L.L.C. (JJPRD)

JJPRD is part of the Johnson Johnson family of companies. JJPRD is headquartered in Raritan, NJ, and has facilities throughout Asia, Europe and the United States. JJPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.

Professor Dr Hartmut Porst has been a consultant and served on advisory boards for Janssen-Cilag.

IR Contacts:

Lesley Fishman: +1 732 524-3922
Louise Mehrotra: +1 732 524-6491

Media Contacts:

Europe:
Stefan Gijssels: + 32 14 60 30 30
Finland:

Juhana Idänpään-Heikkilä: + 358 207 531 300
Sweden:

Katarina Hamnström: +46 730 668 415
US:

Greg Panico +1 908 927-3715

(This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialise, actual results could vary materially from Janssen-Cilag’s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson Johnson. Janssen-Cilag does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

REFERENCES

¹ Buvat, J., et al., Abstracts of the Sexual Medicine Society of North America, SMSNA, 2007 Winter Meeting. December 6-9, 2007. Chicago, Illinois. Patient-reported Treatment Benefit of Dapoxetine for the Treatment of Premature Ejaculation in 22 Countries. J Sex Med 2008. 5(Suppl 1): p. 4-41

² Pryor, J.L., et al., Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet, 2006. 368(9539): p. 929-37

³ McMahon, C., et al., Abstract of the joint congresses of the European and International Societies of Sexual Medicine December 7–11 2008, Brussels, Belgium. Efficacy and Safety of Dapoxetine for Premature Ejaculation: Integrated Analysis of 5 Phase 3 Trials. J Sex Med, 2009. in press

⁴ Grenier, G. and E.S. Byers, The relationships among ejaculatory control, ejaculatory latency, and attempts to prolong heterosexual intercourse. Arch Sex Behav, 1997. 26(1): p. 27-47.

⁵ McMahon, C.G., et al., An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. BJU Int, 2008.

⁶ Porst, H., et al., The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol, 2007. 51(3): p. 816-23; discussion 824.

⁷ Laumann, E.O., A. Paik, and R.C. Rosen, Sexual dysfunction in the United States: prevalence and predictors. Jama, 1999. 281(6): p. 537-44.

⁸ Donatucci, C.F., Etiology of ejaculation and pathophysiology of premature ejaculation. J Sex Med, 2006. 3 Suppl 4: p. 303-8.

⁹ Wolters, J.P. and W.J. Hellstrom, Current concepts in ejaculatory dysfunction. Rev Urol, 2006. 8 (Suppl 4): p. S18-25.

¹⁰ Palmer, N.R. and B.G. Stuckey, Premature ejaculation: a clinical update. Med J Aust, 2008. 188(11): p. 662-6.

Article source: http://www.janssen-cilag.com/news/detail.jhtml?itemname=priligy&action=view